Please assess the completion status of the following clinical trial:

Trial Title: Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of amnestic MCI~* In good general health with no diseases expected to interfere with the study~* Ability to undergo MRI~* Fluent in English~* Stable prescription dosages 1 month prior to testing~* Carrier of the APOE e4 allele (determined by blood draw at screening visit)~Exclusion Criteria:~* Neurological illness/conditions~* Medical illnesses/conditions that may affect brain function~* Prior history of use of any cholinesterase inhibitor~* Instable or severe cardiovascular disease or asthmatic condition

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Exelon transdermal patch (Type: ACTIVE_COMPARATOR): Exelon \[rivastigmine\] transdermal patch
- Placebo transdermal patch (Type: PLACEBO_COMPARATOR): Placebo transdermal patch

Based on this trial design, predict the completion outcome and termination type (if applicable).